Xenografts of cancer cells together with XP-C fibroblasts in the absence or the presence of HGF inhibitors may be expected to be a novel therapeutical approach for XP-C patients suffering from aggressive skin cancers (SCCs). This evidence concerns the gene HGF and skin cancer.